Astellas, Medivation’s cancer drug Xtandi scores new upbeat PhIII results

Emily Mullin

Medivation and Pharma unveiled final on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of (enzalutamide), showing that the delayed tumor growth and prolonged the lives of patients with metastatic prostate who previously have not undergone chemotherapy.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS